SCHEMBL150314

SCHEMBL150314

CSCCC(NC(=O)OCc1ccccc1)C(=O)Nc1cccc(Br)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.54
HDAC1 Q13547 10/20 0.53
HDAC4 P56524 6/20 0.53
HDAC6 Q9UBN7 6/20 0.53
HDAC2 Q92769 4/20 0.50
HDAC3 O15379 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
NCOR2 Q9Y618 2/20 0.50
FNTA P49354 2/20 0.49
FNTB P49356 2/20 0.49
AAK1 Q2M2I8 1/20 0.48
ANPEP P15144 2/20 0.48
MME P08473 1/20 0.48
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL145281 0.85 HDAC1 (0.47) HDAC1HDAC4HDAC6HDAC2HDAC3
SCHEMBL13043797 0.80 CA1 (0.62) CA1FNTAFNTBANPEPMME
SCHEMBL11705090 0.79 FNTA (0.62) CA1FNTAFNTBANPEPMME
SCHEMBL11705092 0.79 FNTA (0.62) CA1FNTAFNTBANPEPMME
SCHEMBL4169134 0.78 FNTA (0.64) CA1FNTAFNTBANPEPMME
SCHEMBL151601 0.78 FNTA (0.64) CA1FNTAFNTBANPEPMME
SCHEMBL1157282 0.78 FNTA (0.64) CA1FNTAFNTBANPEPMME
SCHEMBL4343421 0.78 CA1 (0.55) CA1HDAC1HDAC4HDAC6HDAC2
SCHEMBL4731152 0.77 FNTA (0.61) CA1FNTAFNTBCTSLCTSB
SCHEMBL4731158 0.77 FNTA (0.61) CA1FNTAFNTBCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2391602-B1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-12-04 EP disclosed
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
EP-2391602-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-12-07 EP disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 CA1 3573/4885HDAC1 499/4885HDAC4 966/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 CA1 3573/4885HDAC1 499/4885HDAC4 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.